AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32873251
Drug: 5Gy x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5Gy x 5 fractions of short-course radiation therapy (SCRT) followed by 6 cycles of mFOLFOX-6 plus avelumab
Trial: 34518988
Drug: Tislelizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (monoclonal antibody)
Trial: 32993766
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) in addition to standard treatment (dressings, debridement, antibiotics, load relief)
Trial: 32993766
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (dressings, debridement, antibiotics, load relief)
Trial: 33279389
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori treatment
Trial: 34231473
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of polyethylene glycol (PEG)/ascorbic acid booster solution after the capsule reached the small intestine (group 2)
Trial: 34231473
Drug: 0.5 L
RxNorm normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 L of polyethylene glycol (PEG)/ascorbic acid booster solution after the capsule reached the small intestine (group 3)
Trial: 34231473
Drug: Clear liquid
RxNorm normalized name: Ensure Clear Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear liquid diet and fasting-based bowel preparation (group 1)
Trial: 36041790
Drug: HIF-prolyl-hydroxyl domain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIF-prolyl-hydroxyl domain (PHD) inhibitors (roxadustat, vadadustat, daprodustat)
Trial: 33274388
Drug: Early headgear
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early headgear activator treatment
Trial: 35662833
Drug: Masupirdine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masupirdine 50 mg
Trial: 35662833
Drug: Masupirdine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masupirdine 100 mg
Trial: 32436830
Drug: Intravenous reperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous reperfusion therapy (IVT)
Trial: 32436830
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase combined with mechanical thrombectomy (IAT)
Trial: 32436830
Drug: No cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cerebral reperfusion therapy (NCRT)
Trial: 35614019
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (group 3)
Trial: 34744750
Drug: SHR-1222 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1222 (50 mg, n = 4; 100, 200, 300, or 400 mg, n = 9)
Trial: 32619223
Drug: ZnP (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnP (1.0 g/[hd · d] additional Zn)
Trial: 32619223
Drug: CON (0.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (0.0 g/[hd · d] of additional Zn)
Trial: 35051971
Drug: Specialized outpatient
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized outpatient physical therapy (PT) program
Trial: 34448282
Drug: Probiotics supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics supplemented quadruple therapy
Trial: 34448282
Drug: Probiotics monotherapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics monotherapy
Trial: 32398065
Drug: Antibiotic stewardship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic stewardship programme implemented in intervention arm, including training for family physicians, improved management and peer-review of antibiotic prescribing, improved electronic medical records and smartphone app facilitation, patient education via family physicians, leaflets, and videos.
Trial: 35796224
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% gel
Trial: 35796224
Drug: Topical methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical methotrexate 1% gel
Trial: 34474706
Drug: Subcutaneous allergy
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous allergy immunotherapy for short ragweed, timothy grass, Dermatophagoides pteronyssinus, and cat and dog dander.
Trial: 34474706
Drug: Sublingual allergy
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergy immunotherapy (approved tablets).
Trial: 34474706
Drug: General analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General analysis of dosing practices by U.S. allergists.
Trial: 33028566
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin
Trial: 34178863
Drug: Chlorella vulgaris
RxNorm normalized name: CHLORELLA VULGARIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella vulgaris (CV) 900 mg/day
Trial: 32036492
Drug: 5-fluorouracil/l-leucovorin (5-FU/l-LV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/l-leucovorin (5-FU/l-LV)
Trial: 32036492
Drug: 5-fluorouracil/l-leucovorin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/l-leucovorin plus paclitaxel (FLTAX)
Trial: 32036492
Drug: 5-fluorouracil/l-leucovin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/l-leucovin plus paclitaxel (FLTAX)
Trial: 32086187
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of caffeine
Trial: 32667240
Drug: Collective Narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collective Narrative Therapy Groups (CNTG)
Trial: 33662176
Drug: Bi-monthly household
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-monthly household visits
Trial: 32521976
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (ONS)
Trial: 32865027
Drug: Telehealth visits
RxNorm normalized name: Guaifenesin 100 mg in 5 mL ORAL LIQUID [SelectHealth Tussin DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth visits (weekly to biweekly)
Trial: 32865027
Drug: Telephone calls
RxNorm normalized name: Mosco Corn & Callus Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone calls (monthly)
Trial: 32631710
Drug: Sienna XP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sienna XP (1 mL)
Trial: 32631710
Drug: Sienna XP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sienna XP (1.5 mL)
Trial: 32631710
Drug: Sienna XP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sienna XP (2 mL)
Trial: 32911242
Drug: Multi-component pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-component pre-operative preparation program (including informative booklet, preoperative tour, educational DVD, therapeutic play intervention)
Trial: 32911242
Drug: Informative booklet
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informative booklet as routine information preparation
Trial: 32898357
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 120 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 118.2 ± 10.0 HU.
Trial: 32898357
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 90 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 141.0 ± 18.2 HU.
Trial: 32898357
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: 100 kV tube voltage, CM dose 0.417 g I/kg; O: Mean attenuation 117.6 ± 13.9 HU.
Trial: 32898357
Drug: Group 4:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4: 90 kV tube voltage, CM dose 0.365 g I/kg; O: Mean attenuation 117.3 ± 21.6 HU.
Trial: 33399241
Drug: Palbociclib added
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib added to endocrine therapy
Trial: 34527924
Drug: Paraffin bath
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin bath therapy (20 min, one session per day, for two weeks)
Trial: 34527924
Drug: Fluidotherapy (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluidotherapy (same duration and frequency as paraffin bath therapy)
Trial: 32959458
Drug: CGRP (calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP (calcitonin gene-related peptide) intravenous infusion at 1.5μg/min over 20 minutes
Trial: 32959458
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic saline) intravenous infusion over 20 minutes
Trial: 35899020
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bupivacaine with 5 μg dexmedetomidine (group BD)
Trial: 35899020
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bupivacaine with 10 mg meperidine (group BM)
Trial: 33183558
Drug: Inorganic NO3-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic NO3- tablets (314 mM NO3-)
Trial: 33183558
Drug: Placebo (NO3-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NO3- free tablets)
Trial: 35926074
Drug: Curated social
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curated social web application (interactive website) for COVID-19 vaccine confidence
Trial: 36151976
Drug: Comfort‐in™ injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfort‐in™ injection system (CIS)
Trial: 35909329
Drug: EV 2
RxNorm normalized name: Padcev 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 2 mg + DNG 2-3 mg (n=20)
Trial: 35909329
Drug: EE 0.03
RxNorm normalized name: EE 0.03MG/LEVONORG 0.15MG TAB,28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 0.03 mg + DNG 2 mg (n=20)
Trial: 35909329
Drug: DNG 2
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNG 2 mg (n=19)
Trial: 32142501
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg once daily for 6 weeks
Trial: 32142501
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg once daily for 6 months
Trial: 34487086
Drug: 2-hour Oral
RxNorm normalized name: dextroamphetamine 2 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour Oral Glucose Tolerance Test (OGTT)
Trial: 33934519
Drug: Durlobactam 4
RxNorm normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durlobactam 4 g (supratherapeutic dose)
Trial: 33934519
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus moxifloxacin 400 mg (open-label)
Trial: 33313732
Drug: Low-dose chiropractic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chiropractic care (1 to 5 visits)
Trial: 33313732
Drug: Higher-dose chiropractic
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose chiropractic care (8 to 12 visits)
Trial: 33313732
Drug: Monthly chiropractic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly chiropractic chronic pain management for 10 months
Trial: 34086481
Drug: Induction neoadjuvant
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction neoadjuvant hormonal therapy (HT) with fulvestrant 500 mg (with or without goserelin)
Trial: 34086481
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg plus palbociclib
Trial: 34086481
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg plus placebo
Trial: 35897310
Drug: Lactiplantibacillus plantarum
RxNorm normalized name: Lactiplantibacillus plantarum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactiplantibacillus plantarum SNK12 (50 mg/day)
Trial: 35897310
Drug: Lactiplantibacillus plantarum
RxNorm normalized name: Lactiplantibacillus plantarum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactiplantibacillus plantarum SNK12 (150 mg/day)
Trial: 33782036
Drug: Ramipril (1.25-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (1.25-10 mg/d)
Trial: 33782036
Drug: Non-RAS inhibition
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-RAS inhibition therapy
Trial: 34529065
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation at hospital admission
Trial: 34529065
Drug: Standard, physician-acquired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, physician-acquired medication history (Control)
Trial: 33636242
Drug: Microneedle patch
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle patch plus 5% topical lidocaine
Trial: 33636242
Drug: Patch without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patch without microneedles plus 5% topical lidocaine
Trial: 35535436
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (VAR, BUP, NRT)
Trial: 32425111
Drug: Low-Na solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Na solution (112 mmol/L Na and 2% glucose)
Trial: 32425111
Drug: Standard-Na solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Na solution (133 mmol/L Na and 1.5% glucose)
Trial: 34802925
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration
Trial: 33813580
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: 33385299
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg twice daily for 6 months
Trial: 32218417
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment complex (dietary and proton pump inhibitor drugs)
Trial: 615245085
Drug: Collagenase Clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase Clostridium histolyticum (CCH) intralesional injection
Trial: 32805428
Drug: Lipid-containing tear
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-containing tear supplement (Systane Complete)
Trial: 34700598
Drug: IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT with ISBT boost (initial dose 50Gy with IMRT followed by 24.5Gy dose in 12 fractions)
Trial: 32130284
Drug: Anorganic xenograft
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anorganic xenograft added at the time of flapless, one-stage placement of a sloped-platform implant
Trial: 33453095
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation (TF) - Product A
Trial: 33972256
Drug: Etesevimab (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etesevimab (2.5 to 50 mg/kg)
Trial: 32852530
Drug: Fingolimod, 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod, 0.25 mg
Trial: 32852530
Drug: Glatiramer acetate,
RxNorm normalized name: Glatiramer Acetate, 20 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate, 20 mg
Trial: 32473673
Drug: elexacaftor plus
RxNorm normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: elexacaftor plus tezacaftor plus ivacaftor combination regimen
Trial: 33591125
Drug: Subacromial hyaluronate
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subacromial hyaluronate injection (2 mL, 20 mg, hyaluronate 1% (500 to 700 kDa))
Trial: 35437111
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine (CC‐486)
Trial: 33560633
Drug: Wrist actigraphy
RxNorm normalized name: histamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wrist actigraphy for hourly activity counts
Trial: 33306506
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) intake (g/d)
Trial: 33306506
Drug: Isoflavones intake
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones intake (mg/d)
Trial: 33306506
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake (mg/d)
Trial: 33306506
Drug: Choline intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline intake (mg/d)
Trial: 33306506
Drug: Carbohydrates intake
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrates intake among rs738409 G-allele carriers
Trial: 33306506
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs intake among rs738409 G-allele carriers
Trial: 33306506
Drug: Isoflavones intake
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones intake among rs738409 G-allele carriers
Trial: 33306506
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake among rs738409 G-allele carriers
Trial: 33306506
Drug: Choline intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline intake among rs738409 G-allele carriers
Trial: 35760720
Drug: Evolocumab (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (420 mg monthly)
Trial: 33030020
Drug: Topical 1:1000
RxNorm normalized name: thimerosal topical 1:1000 topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1:1000 epinephrine
Trial: 33030020
Drug: Topical 1:10
RxNorm normalized name: thimerosal topical 1:1000 topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1:10 000 epinephrine
Trial: 35065636
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg of curcuminoid + 5 mg piperine)
Trial: 36370716
Drug: q3EC-P (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q3EC-P (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks followed by paclitaxel 175 mg/m2 every 3 weeks)
Trial: 36370716
Drug: q3FEC-P (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q3FEC-P (fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 every 3 weeks followed by paclitaxel 175 mg/m2 every 3 weeks)
Trial: 36370716
Drug: q2EC-P (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q2EC-P (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks followed by paclitaxel 175 mg/m2 every 2 weeks)
Trial: 36370716
Drug: q2FEC-P (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q2FEC-P (fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 every 2 weeks followed by paclitaxel 175 mg/m2 every 2 weeks)
Trial: 32556496
Drug: Literature-mining approach
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Literature-mining approach analyzing cancer immunotherapy publications
Trial: 32556496
Drug: Research topics
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Research topics in cancer immunotherapy
Trial: 35512165
Drug: Arm sling
RxNorm normalized name: Universal Arm Sling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm sling with kinesiotaping therapy (group K)
Trial: 35886615
Drug: Weekly educational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly educational newsletters (Control)
Trial: 33151961
Drug: miR-21 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: miR-21 inhibitor
Trial: 36451359
Drug: Soft Touch
RxNorm normalized name: Soft Touch Blue
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soft Touch Training (STT) - guided soft brushing of selected skin regions, 15-minute daily sessions for 4 weeks
Trial: 36451359
Drug: Progressive Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive Muscle Relaxation (PMR) - guided tensing and relaxing of selected muscle regions, 15-minute daily sessions for 4 weeks